Showing 7311-7320 of 8894 results for "".
- New International Recommendations for Treating Acne Scars with Energy-Based Deviceshttps://practicaldermatology.com/news/new-international-recommendations-for-treating-acne-scars-with-energy-based-devices/2460990/Energy-based devices are the first-line treatments for a variety of acne scars, according to new international consensus recommendations published in Lasers in Surgery and Medicine. For the first time
- National Rosacea Society Awards 2021 Research Grantshttps://practicaldermatology.com/news/national-rosacea-society-awards-2021-research-grants/2460988/The National Rosacea Society has awarded funding for two new studies in addition to continuing support for two ongoing studies as part of its
- With New Agreement, DermTech Melanoma Test Available Through DermatologistOnCallhttps://practicaldermatology.com/news/with-new-agreement-dermtech-melanoma-test-available-through-dermatologistoncall/2460987/The DermTech Melanoma Test is now available through DermatologistOnCall’s telemedicine platform. The DermTech Melanoma Test is a non-invasive test used to painlessly collect cellular material from the surface of a patient’s mole via t
- PsA Treatment Snapshot: Study Highlights Trends in PsA Treatment Since 2018https://practicaldermatology.com/news/psa-treatment-snapshot-study-highlights-trends-in-psa-treatment-since-2018/2460985/There’s been a significant increase in anti-IL17 and anti-phosphodiesterase-4 (anti-PDE4) medications being used as initial treatment for psoriatic arthritis (PsA) since 2018, which may reflect their inclusion as potential initial therapy in the American College of Rheumatology/National Pso
- Gryphon Investors to Acquire Revision Skincarehttps://practicaldermatology.com/news/gryphon-investors-to-acquire-revision-skincare/2460984/Gryphon Investors is set to acquire Revision Skincare and Goodier Cosmetics. The middle-market private equity firm has signed a definitive agreement to acquire the skincare company, with an anticipating closing date this year. Financial terms of the transaction were not disclosed.
- Skyrizi Improves PsA Signs and Symptomshttps://practicaldermatology.com/news/skyrizi-improves-psa-signs-and-symptoms/2460981/AbbVie’s risankizumab (SKYRIZI) showed greater improvements in psoriatic arthritis (PsA) signs and symptoms compared to treatment with placebo at week 24 in two Phase 3 clinical trials, according to research slated to be presented American College of Rheumatology (ACR) Convergence 2021.
- Study: Infection Rates in PsA Patients on Biologics Are Decreasinghttps://practicaldermatology.com/news/study-infection-rates-in-psa-patients-on-biologics-are-decreasing/2460979/Infection rates among people with psoriatic arthritis (PsA) taking biologics decreased from 2012 to 2017, according to new research presented at ACR Convergence, the American College of Rheumatology’s an
- RoC Skincare Marks the First National Retinol Dayhttps://practicaldermatology.com/news/roc-skincare-marks-the-first-national-retinol-day/2460977/Just as Americans set back their clocks this weekend, retinol can help turn back the clock on fine lines and wrinkles. That's the message from RoC® Skincare in honor of the first-ever National Retinol Day on Sunday. National Retinol Day has been registered for annual
- Sun Pharma’s WINLEVI for Acne Now Availablehttps://practicaldermatology.com/news/sun-pharmas-winlevi-for-acne-now-available/2460974/WINLEVI (clascoterone) cream 1% is now available the US, according to Sun Pharmaceutical Industries Limited. A first-in-class topical androgen receptor inhibitor, WINLEVI was approved by FDA in August 2020 for the topical treatment of acne vulgaris in patients 12 yea
- Lutronic Rolls Out Derma V Dermatology Platformhttps://practicaldermatology.com/news/lutronic-rolls-out-derma-v-dermatology-platform/2460972/Lutronic is launching Derma V, a dermatology workstation that comprises a 532nm green laser, a 1064nm laser plus ICD cooling and IntelliTrack. "We created a device that brings the essential lasers that skin specialists need for their daily work - vascular, pigment and rejuvenation